WO1996029076A3 - Traitement des affections instestinales inflammatoires par la cotinine - Google Patents

Traitement des affections instestinales inflammatoires par la cotinine Download PDF

Info

Publication number
WO1996029076A3
WO1996029076A3 PCT/US1996/003000 US9603000W WO9629076A3 WO 1996029076 A3 WO1996029076 A3 WO 1996029076A3 US 9603000 W US9603000 W US 9603000W WO 9629076 A3 WO9629076 A3 WO 9629076A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
cotinine
treatment
bowel disorders
symptoms
Prior art date
Application number
PCT/US1996/003000
Other languages
English (en)
Other versions
WO1996029076A2 (fr
Inventor
Robert M Keenan
Original Assignee
Lectec Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lectec Corp filed Critical Lectec Corp
Priority to AU50926/96A priority Critical patent/AU5092696A/en
Publication of WO1996029076A2 publication Critical patent/WO1996029076A2/fr
Publication of WO1996029076A3 publication Critical patent/WO1996029076A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé thérapeutique qui permet de traiter les symptomes des affections intestinales inflammatoires par administration de la cotinine ou bien un sel pharmaceutiquement acceptable de ladite cotinine à un patient ayant besoin du traitement considéré. La posologie décrite permet d'éliminer efficacement au moins l'un des symptomes dans les affections intestinales inflammatoires.
PCT/US1996/003000 1995-03-17 1996-03-06 Traitement des affections instestinales inflammatoires par la cotinine WO1996029076A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50926/96A AU5092696A (en) 1995-03-17 1996-03-06 Treatment of inflammatory bowel disorders with cotinine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40560795A 1995-03-17 1995-03-17
US08/405,607 1995-03-17

Publications (2)

Publication Number Publication Date
WO1996029076A2 WO1996029076A2 (fr) 1996-09-26
WO1996029076A3 true WO1996029076A3 (fr) 1997-02-13

Family

ID=23604403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003000 WO1996029076A2 (fr) 1995-03-17 1996-03-06 Traitement des affections instestinales inflammatoires par la cotinine

Country Status (2)

Country Link
AU (1) AU5092696A (fr)
WO (1) WO1996029076A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034605A1 (fr) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Utilisation de nicotine pour traiter une hepatopathie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023045A1 (fr) * 1992-05-18 1993-11-25 Pharmaco Behavioral Associates, Inc. Utilisation de la cotinine pour calmer le syndrome de sevrage du tabac

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023045A1 (fr) * 1992-05-18 1993-11-25 Pharmaco Behavioral Associates, Inc. Utilisation de la cotinine pour calmer le syndrome de sevrage du tabac

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAMESON J S ET AL: "THE EFFECT OF SMOKING ON COLONIC PRESSURE ACTIVITY", 94TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION, BOSTON, MASSACHUSETTS, USA, MAY 15-21, 1993. GASTROENTEROLOGY, 104 (4 SUPPL.). 1993. A527., XP000600394 *
PULLAN RD ET AL: "Transdermal nicotine for active ulcerative colitis", N ENGL J MED, MAR 24 1994, 330 (12) P811-5, UNITED STATES, XP000600452 *
SRIVASTAVA ED ET AL: "Effect of nicotine and cotinine on the production of oxygen free radicals by neutrophils in smokers and non-smokers.", HUM TOXICOL, NOV 1989, 8 (6) P461-3, ENGLAND, XP000600409 *
VAN DIJK J.P.M. ET AL: "Nicotine inhibits cytokine synthesis by mouse colonic mucosa", EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 278/1 (R11-R12), NETHERLANDS, XP000600463 *

Also Published As

Publication number Publication date
WO1996029076A2 (fr) 1996-09-26
AU5092696A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
CA2310845A1 (fr) Traitement de troubles et de maladies neuromusculaires a l'aide de differents serotypes de botulinum
CA2260145A1 (fr) Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
CA2146647A1 (fr) Traitement d'affections auto-immunes et inflammatoires
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
EP0945135A3 (fr) Traitement de la maladie d'Alzheimer et immunomodulation par les delta 5 androstenes
CA2186673A1 (fr) Utilisation d'acides gras dans le traitement de la choree de huntington
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
CA2149924A1 (fr) Utilisation de la phenserine pour traiter les troubles cognitifs
CA2150184A1 (fr) Composition pharmaceutique pour le traitement des affections intestinales inflammatoires
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO1997009976A3 (fr) Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc
WO1999004772A3 (fr) Levobupivacine et son utilisation
EP0957925A4 (fr) Traitement de l'arthrose par administration de poly-n-acetyl-d-glucosamine
HK1022432A1 (en) Administration of histamine for therapeutic purposes.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
WO1999048489A3 (fr) Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
AU4312593A (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
CA2150183A1 (fr) Composition pharmaceutique pour le traitement des affections hemoroidales
WO1996005836A3 (fr) Procedes de traitement de symptomes dus au froid au moyen de la pentoxifylline
WO1996029076A3 (fr) Traitement des affections instestinales inflammatoires par la cotinine
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA